Introduction 49
Neurodegenerative dementias constitute a broad category of brain diseases that cause a long 50 term and often gradual decrease in the ability to think and remember that is great enough to 51 affect a person's daily functioning. The most common type of dementia is Alzheimer's 52 disease (AD) that makes up 50% to 70% of the cases (98). AD causes a progressive loss of 53 cognitive abilities with short-term memory impairment being the most typical initial 54 symptom. However, there are also atypical clinical presentations of AD, e.g., primary 55 progressive aphasia or posterior cortical atrophy (52), and there are many other dementia-56 causing diseases that may be important differential diagnoses (70) . 57 58 A dementia diagnosis is usually based on the history of the illness, the pattern of cognitive 59 deficits, with investigations including, e.g., blood work used to rule out other possible (non-60 cerebral) causes, and imaging both to rule out alternative diagnoses and to provide positive 61 evidence for a given diagnosis. Specific dementia diagnoses can be made using clinical 62 criteria that may be supplemented by information from biomarkers (20), but a definite 63 diagnosis requires autopsy confirmation, based on the fact that each of the degenerative 64 dementia-causing brain disorders is characterised by more or less distinct neuropathology 65 (35) . A striking feature is that most neurodegenerative dementias show aggregates or 66 inclusions of specific proteins in the brain extracellular matrix or within neurons or other cell 67 types of the brain (43). Some researchers have even classified them as "proteopathies" (90) . 68 69 Neuropathologically, AD is characterized by neuronal loss in specific brain regions, 70 intraneuronal neurofibrillary tangles composed of aggregated and often hyperphosphorylated 71 tau protein, and extracellular neuritic plaques that are deposits of amyloid β (Aβ) peptides, 72 mainly ending at amino acid 42 (7). Additionally, synapse loss (71) It has been much more difficult to establish robust blood biomarkers for plaque pathology. Aβ 117 proteins can be measured in plasma but the correlation with cerebral β-amyloidosis is absent 118 or weak (statistically significant but clinically meaningless) (38, 61), and plasma Aβ 119 concentrations are probably influenced by production in platelets and other extra-cerebral 120 tissues (103). Pilot data suggest associations of the concentrations of a number of plasma 121
proteins (e.g., pancreatic polypeptide Y, IgM, chemokine ligand 13, interleukin 17, vascular 122 cell adhesion protein 1, α2-macroglobulin, apolipoprotein A1 and complement proteins) with 123 amyloid burden in the brain (12, 97, 100) . However, these data should be interpreted with 124 some caution, as they are derived from multi-marker panels and as a mechanistic 125 understanding of the associations is currently lacking. is to bind to and stabilize tubulin multimers in neuronal axons. Tangle-marked neurons 134 release phosphorylated tau that can be measured in CSF by ELISA using antibody 135 combinations specific against mid-domain phospho-tau epitopes. AD patients have increased 136 CSF P-tau concentrations (62). CSF P-tau concentration correlates weakly with 137 neurofibrillary tangle pathology in AD (11, 72); a finding that has been replicated in recent 138 tau PET imaging studies (13), although the results are less clear than for CSF Aβ42. A major 139 outstanding research question is why other tauopathies, including some forms of FTD and 140 progressive supranuclear palsy, do not show P-tau increase, at least not as systematically as 141 seen in AD. It is possible that these disorders show disease-specific tau phosphorylation, or 142 that tau is processed or truncated in a way that is not recognized by available assays. Another 143 potential explanation for the AD specificity of CSF P-tau is if the amount of pathology were 144 simply greater in AD than in other tauopathies (there is to the best of my knowledge no 145 published data addressing this hypothesis). CSF P-tau is currently considered the most 146 specific biomarker for AD; except for herpes encephalitis (25) and superficial CNS siderosis 147 (36, 42) , no other condition shows systematic increase in this biomarker (104). 148
Blood 150
There are so far no reliable blood biomarkers for neurofibrillary tangle pathology, although 151 there is an emerging literature on P-tau concentrations in neuronally derived blood exosomes 152 with contrasting results in regards to association with AD (75, 99) . Total tau (T-tau), measured using assays with antibodies against mid-domain tau amino acid 159 sequences that are not phosphorylated, can be used as a general marker of neuroaxonal 160 degeneration/injury in AD. AD patients have increased CSF T-tau concentrations (62), and 161 the higher the increase, the more intense neurodegenerative process (92). However, CSF T-tau 162 increase is not specific for AD; it is also seen in, e.g., Creutzfeldt-Jakob disease (CJD) (67) (101) and 60) . Another microglial marker, the C-C chemokine receptor 2, is 218 expressed on monocytes and one of its ligands, C-C chemokine ligand 2 (CCL2), that can be 219 produced by microglia, is present at increased concentration in AD CSF (15, 23, 24) . Most 220 studies suggest that these increases are modest with large overlaps between cases and 221 controls, if compared to the more prominent changes seen in traditional neuroinflammatory 222 conditions, such as multiple sclerosis (58) suggesting that α-synuclein may also be an non-specific marker of neurodegeneration (56, 59, 243 79, 84, 96) . This has been reported not only in AD and CJD, but also in DLB, where there 244 may be a competition between aggregation of α-synuclein into Lewy bodies and release of the 245 protein from degenerating synapses, making the data complex to interpret (40). Currently 246 available assays for α-synuclein measure total amounts of the protein and not Lewy body-247 specific isoforms; sensitive and specific assays for the latter would resolve this issue. The BBB is the interface between the blood and the brain, regulating the transport of 286 molecules between the blood and the central nervous system. Its primary function is to 287 maintain the tightly controlled microenvironment of the brain, which is a critical part in 288 sustaining a healthy nervous system. The most commonly used measure of BBB function in 289 clinical laboratory practice is the CSF/serum albumin ratio (86). Proteins cross the BBB at 290 different rates, depending on their hydrodynamic radii, with passage of larger proteins being 291 more restricted than that of smaller proteins (21). As albumin is not produced in the CNS, 292 CSF/serum albumin ratio can be used to assess the integrity of the BBB. A large number of 293 studies have examined the CSF/serum albumin ratio in AD without finding any clear increase 294 (61). In contrast, CSF/serum albumin ratio is increased in VaD, suggesting that 295 cerebrovascular changes are associated with a leakier barrier (78, 91). 296
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Blood 298
There are no established blood tests for BBB function, although a number of candidates do 299 exist. One such protein is occludin, a 65-kDa integral membrane protein that contributes to 300 tight junction stabilization at barriers (17). However, this protein is not specific to the brain, 301 but also expressed at high levels in testis, kidney, liver and lung (68), which may explain why 302 this marker, at least when examined in traumatic brain injury, has failed to produce 303 interpretable results (74). 
